This study is currently recruiting participants.
Number
04-C-0102
Sponsoring Institute
National Cancer Institute (NCI)
Recruitment Detail
Type: Enrolling by Invitation Gender: Male & Female Min Age: 1 Years Max Age: 75 Years
Referral Letter Required
Yes
Population Exclusion(s)
Neonates
Keywords
Acute Lymphoblastic Leukemia; Acute Lymphocytic Leukemia; Pediatric Blood Disorders; Hodgkins and non-Hodgkins lymphoma; MDS; Natural History
Recruitment Keyword(s)
None
Condition(s)
Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome (MDS); Non-Hodgkins Lymphoma; Acute Myelogenous Leukemia; Hodgkins Lymphoma
Investigational Drug(s)
Investigational Device(s)
Intervention(s)
Supporting Site
National Cancer Institute
- Examination of individual cancer cells and to search for differences compared to other types of cancer and normal cells
- Examination of the chromosomes and genes in cancer cells and to search for differences compared to other types of cancer and normal cells
- Development of sensitive methods to detect small amounts of cancer that remain after treatment
- Search for new cancer proteins that might serve as targets for treatment
- Investigation of methods to develop cancer vaccines.
Patients from >= 1 to 75 years of age with acute lymphocytic leukemia, acute myelogenous leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, juvenile myelomonocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, and other hematologic malignancies may be eligible for this study.
Blood or bone marrow samples will be collected when sampling is required for the patient's medical care. Cells from some individuals will be grown in test tubes, establishing cell lines or in animals, establishing xenograft models. (A xenograft is transplantation of cells of one species to another species.)
--Back to Top--
INCLUSION CRITERIA Confirmed pathological diagnosis of any hematologic malignancy or pre-malignant blood disorder, including but not restricted to the following: Acute Lymphocytic Leukemia (ALL) Acute Myelogenous Leukemia (AML) Myelodysplastic Syndrome (MDS) Chronic Myelogenous Leukemia (CML) Juvenile Myelomonocytic Leukemia (JMML, J-CML) Non-Hodgkin's Lymphoma (NHL) Hodgkin's Disease Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care. Patient age: >= 1 to 75 years. Prior therapy: no restrictions Subject, parent/guardian, legally authorized representative (LAR), or durable power of attorney must be able to give informed consent and sign the informed consent document. EXCLUSION CRITERIA None
Confirmed pathological diagnosis of any hematologic malignancy or pre-malignant blood disorder, including but not restricted to the following:
Acute Lymphocytic Leukemia (ALL)
Acute Myelogenous Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Chronic Myelogenous Leukemia (CML)
Juvenile Myelomonocytic Leukemia (JMML, J-CML)
Non-Hodgkin's Lymphoma (NHL)
Hodgkin's Disease
Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care.
Patient age: >= 1 to 75 years.
Prior therapy: no restrictions
Subject, parent/guardian, legally authorized representative (LAR), or durable power of attorney must be able to give informed consent and sign the informed consent document.
EXCLUSION CRITERIA
Principal Investigator
Referral Contact
For more information: